|Dr. Taylor H. Schreiber M.D., Ph.D.||Co-Founder, CEO & Director||783.75k||N/A||1980|
|Dr. Abhinav A. Shukla Ph.D.||Chief Technical Officer||567.4k||N/A||1973|
|Dr. Arundathy Nirmalini Pandite M.B.A., M.D.||Chief Medical Officer||678.76k||N/A||1959|
|Mr. Andrew R. Neill M.B.A.||Chief Financial Officer||N/A||N/A||1986|
|Mr. Conor Richardson CPA||Vice President of Investor Relations||N/A||N/A||N/A|
|Dr. Stephen Stout J.D., Ph.D.||General Counsel, Corporate Secretary and Chief Ethics & Compliance Officer||N/A||N/A||N/A|
|Ms. Casi DeYoung||Chief Business Officer||523.48k||N/A||1971|
|Dr. Thomas Lampkin Pharm.D.||Senior Vice President of Regulatory Affairs||N/A||N/A||N/A|
|Mr. George Fromm Ph.D.||Chief Scientific Officer of ARC Platform||N/A||N/A||N/A|
|Mr. Suresh de Silva Ph.D.||Chief Scientific Officer of GADLEN Platform||N/A||N/A||N/A|
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. The company was incorporated in 2016 and is headquartered in Austin, Texas.
Shattuck Labs, Inc.’s ISS governance QualityScore as of 1 December 2023 is 6. The pillar scores are Audit: 3; Board: 6; Shareholder rights: 8; Compensation: 7.